Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations-Reference-Cited by-同舟云学术

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

Published:2016-09 Issue:9 Volume:11 Page:1493-1502
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Schrock Alexa B.,Frampton Garrett M.,Suh James,Chalmers Zachary R.,Rosenzweig Mark,Erlich Rachel L.,Halmos Balazs,Goldman Jonathan,Forde Patrick,Leuenberger Kurt,Peled Nir,Kalemkerian Gregory P.,Ross Jeffrey S.,Stephens Philip J.,Miller Vincent A.,Ali Siraj M.,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

2. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer;Farago;J Thorac Oncol,2015

3. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress;Cui;J Med Chem,2014

4. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer;Okuda;Cancer Sci,2008

5. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements;Kazandjian;Oncologist,2014

Cited by 308 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the future of cancer diagnosis – promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer;Translational Research;2024-10

2. Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology;Lung Cancer;2024-10

3. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study;Lung Cancer;2024-10

4. Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer;CLIN LUNG CANCER;2024

5. Molecular analysis of non-small cell lung cancer using a dual-targeted DNA and RNA comprehensive genomic profiling panel;Respiratory Investigation;2024-09